Wendy Lane
Endocrinology, Diabetes & Metabolism · Asheville, NCNPI 1073644175
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 64.3% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2019 at $141,779 and has fallen 61.9% since, to $53,977 in 2025. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 815 payments — averaging $597.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$313K
- Dexcom, Inc.$74K
- Novo Nordisk AS$63K
- Xeris Pharmaceuticals, Inc.$15K
- Insulet Corporation$8K
- Vertex$6K
- plus $9K from 39 others
Across 574 payments — averaging $2387.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$741K
- Novo Nordisk AS$205K
- Insulet Corporation$163K
- Dexcom, Inc.$99K
- AbbVie$73K
- Lexicon Pharmaceuticals, Inc.$38K
- plus $53K from 3 others
What the payments were for
- Consulting fees$78,99716%
- Speaking & faculty fees$292,05960%
- Travel & lodging$99,86520%
- Food & beverage$16,2093%
- Education$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$136,958
- RYBELSUS$67,743
- DEXCOM G7 GSS (161)$41,422
- Victoza$37,473
- Tresiba$30,631
- DEXCOM G6 TRANSMITTER$15,968
- GVOKE PFS$14,404
- DEXCOM STELO GLUCOSE BIOSENSOR$10,617
- DEXCOM CGM$8,678
- Omnipod$7,062
- DEXCOM G6 CGM SYSTEM$6,358
- ZEGALOGUE$1,600
- t-slim insulin pump$1,000
- TWIIST$420
- t:slim X2 insulin pump$250
- MINIMED 780G$146
How this compares
$487,305 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $91,404 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 71 | $87,111 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $61,409 |
| FarxigaDapagliflozin Propanediol | 36 | $42,626 |
| MounjaroTirzepatide | 29 | $35,817 |
| JardianceEmpagliflozin | 21 | $33,573 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $32,465 |
| TrulicityDulaglutide | 14 | $18,367 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $13,262 |
| HumalogInsulin Lispro | 29 | $10,226 |
| Novolog FlexpenInsulin Aspart | 25 | $7,549 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $3,930 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 21 | $3,131 |
| SynthroidLevothyroxine Sodium | 26 | $1,613 |
| Levothyroxine Sodium | 89 | $897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $313,311 | $91,40457 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $791 | $64,41072 claims |
| AstraZenecaFarxiga | $560 | $42,62636 claims |
| Boehringer IngelheimJardiance | $147 | $33,57321 claims |
| AbbVieSynthroid | $288 | $1,61326 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $89789 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Asheville
- Richard DoddAsheville$526K
- Victor MarlarAsheville$483K
- Lauren BernsteinAsheville$307K
- Stephen WeinribAsheville$11K
- Hilary ThomasAsheville$10K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.